-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Jiaxing, China and Burlingame, California, U.
S.
October 26, 2021/PRNewswire/ - Heji Pharmaceuticals announced that its first ITK inhibitor in the world to enter the clinical development stage, the clinical use of CPI-818 for oral administration The trial application was approved by the NMPA Drug Approval Center for clinical trial approval, and it is intended to be used for relapsed/refractory T-cell lymphoma
.
Heji Pharmaceutical has the authority of CPI-818 Greater China
CPI-818 is an inhibitor that can strongly inhibit ITK kinase.
In the first human clinical trials conducted in the United States, South Korea, and Australia, it has shown definite efficacy and good safety and tolerability
.
As of February 17, 2021, a total of 25 patients worldwide (16 in the dose-escalation phase and 9 in the expansion phase) have received CPI-818 treatment
Dr.
Richard Miller, co-founder and chairman of Heji Pharmaceutical, said: “I am very pleased that CPI-818 has been approved for clinical use in China.
We will work with experts in the field of lymphoma in China to fully advance the progress of CPI-818 clinical trials, strive to be approved for listing in China as soon as possible, and bring revolutionary solutions to patients with relapsed/refractory T-cell lymphoma To meet urgent clinical needs
.
"
Director of the Chinese Society of Clinical Oncology (CSCO), Secretary-General of the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology (CSCO), Professor Song Yuqin from the Lymphoma Department of Peking University Cancer Hospital, said: "Relapsed/refractory T-cell lymphoma is non-Hodgkin's lymphoma.
A major problem in clinical work, the current five-year survival rate of most patients is only 10-30%
.
We are very pleased to see that Heji Pharmaceutical has brought new target ITK inhibitors to China.
About CPI-818
CPI-818 can strongly inhibit ITK kinase and is highly selective without affecting normal T cell proliferation and immune response
.
Interleukin-2 (IL-2) induces tyrosine kinase (ITK), which was first discovered in 1992, with a molecular weight of 72kDa protein kinase, which plays an essential role in the activation, differentiation and proliferation of Th2 cells
About Heji Pharmaceutical
Heji Pharmaceutical is an innovative drug company dedicated to tumors and autoimmune diseases
.
In October 2020, Heji Pharmaceuticals completed a 280 million yuan A round of financing, which was jointly invested by Betta Funds, Hisun Pharmaceuticals, Tiger Pharmaceuticals, and Fusheng Investment, and was established in a strategic cooperation with Corvus Pharmaceuticals (CRVS) of the United States
Corvus Pharmaceuticals is a biopharmaceutical company in the clinical stage
.
Corvus's main pipeline product is mupadolimab (CPI-006), which is a humanized monoclonal antibody against CD73, which has shown immunomodulatory activity and immune cell activation in preclinical studies
